Market Overview

17 Healthcare Stocks Moving In Monday's Pre-Market Session

Share:

Gainers

Equillium, Inc. (NASDAQ:EQ) shares rose 261.12% to $11.52 during Monday's pre-market session.

electroCore, Inc. (NASDAQ:ECOR) stock increased by 184.70% to $2.42.

Altimmune, Inc. (NASDAQ:ALT) shares moved upwards by 49.88% to $33.50.

Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) stock rose 17.04% to $3.09. The most recent rating by Mizuho, on Apr 23, is at Buy, with a price target of $14.

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) shares increased by 12.62% to $0.31. According to the most recent rating by Oppenheimer, on Jun 24, the current rating is at Perform.

Centogene, Inc. (NASDAQ:CNTG) shares increased by 8.57% to $14.44. The most recent rating by Baird, on Apr 24, is at Outperform, with a price target of $20.

Cassava Sciences, Inc. (NASDAQ:SAVA) shares rose 8.54% to $3.62. According to the most recent rating by HC Wainwright & Co., on May 18, the current rating is at Neutral.

BioNTech, Inc. (NASDAQ:BNTX) stock moved upwards by 7.73% to $75.80. The most recent rating by SVB Leerink, on Jul 2, is at Market Perform, with a price target of $42.

Tonix Pharmaceuticals, Inc. (NASDAQ:TNXP) stock moved upwards by 7.56% to $0.69.

Seres Therapeutics, Inc. (NASDAQ:MCRB) shares moved upwards by 7.53% to $4.85.

 

Losers

NextCure, Inc. (NASDAQ:NXTC) stock declined 10.52% to $16 during Monday's pre-market session. According to the most recent rating by Benchmark, on Jun 1, the current rating is at Hold.

Endologix, Inc. (NASDAQ:ELGX) shares decreased by 5.56% to $0.26. According to the most recent rating by BTIG, on May 12, the current rating is at Neutral.

Mesoblast, Inc. (NASDAQ:MESO) stock declined 3.85% to $12.52. The most recent rating by HC Wainwright & Co., on May 28, is at Buy, with a price target of $21.

Dynatronics, Inc. (NASDAQ:DYNT) shares decreased by 3.49% to $0.83. The most recent rating by Aegis Capital, on May 19, is at Buy, with a price target of $1.

9 Meters Biopharma, Inc. (NASDAQ:NMTR) shares decreased by 3.40% to $0.53.

CHF Solutions, Inc. (NASDAQ:CHFS) stock declined 3.31% to $0.59.

Arbutus Biopharma, Inc. (NASDAQ:ABUS) stock declined 3.23% to $1.80. The most recent rating by Wedbush, on May 19, is at Outperform, with a price target of $4.

 

Related Articles (EQ + ECOR)

View Comments and Join the Discussion!

Posted-In: Healthcare Stocks Pre-Market MoversPre-Market Outlook Markets Movers Trading Ideas